US-based Biogen Idec has received approval from the European Commission (EC) for its Tecfidera (dimethyl fumarate) as a first-line oral treatment for people with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).
Biogen’s multiple sclerosis drug Tecfidera obtains EU approval click here
Filed under: EU PIPELINE Tagged: Dimethyl fumarate, EU, Tecfidera
